- Home
- KSS vs NEO Comparison
KSS vs NEO Comparison
Compare KSS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- NEO
- Stock Information
- Founded
- KSS 1962
- NEO 2001
- Country
- KSS United States
- NEO United States
- Employees
- KSS N/A
- NEO N/A
- Industry
- KSS Department/Specialty Retail Stores
- NEO Precision Instruments
- Sector
- KSS Consumer Discretionary
- NEO Health Care
- Exchange
- KSS Nasdaq
- NEO Nasdaq
- Market Cap
- KSS 931.8M
- NEO 963.9M
- IPO Year
- KSS 1992
- NEO 1999
- Fundamental
- Price
- KSS $10.74
- NEO $5.16
- Analyst Decision
- KSS Sell
- NEO Buy
- Analyst Count
- KSS 13
- NEO 8
- Target Price
- KSS $8.54
- NEO $12.14
- AVG Volume (30 Days)
- KSS 21.0M
- NEO 2.7M
- Earning Date
- KSS 08-27-2025
- NEO 07-29-2025
- Dividend Yield
- KSS 4.66%
- NEO N/A
- EPS Growth
- KSS N/A
- NEO N/A
- EPS
- KSS 1.09
- NEO N/A
- Revenue
- KSS $16,072,000,000.00
- NEO $689,189,000.00
- Revenue This Year
- KSS N/A
- NEO $13.83
- Revenue Next Year
- KSS N/A
- NEO $11.35
- P/E Ratio
- KSS $9.85
- NEO N/A
- Revenue Growth
- KSS N/A
- NEO 9.70
- 52 Week Low
- KSS $6.04
- NEO $4.73
- 52 Week High
- KSS $22.00
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- KSS 51.23
- NEO 29.52
- Support Level
- KSS $11.81
- NEO $4.81
- Resistance Level
- KSS $21.39
- NEO $6.61
- Average True Range (ATR)
- KSS 1.47
- NEO 0.40
- MACD
- KSS -0.11
- NEO -0.17
- Stochastic Oscillator
- KSS 12.70
- NEO 17.46
About KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.